<DOC>
	<DOCNO>NCT00387764</DOCNO>
	<brief_summary>This open-label , international , multi-center study design provide access pazopanib subject enrol Phase III renal cell carcinoma study ( VEG105192 ) progress placebo . Subjects receive 800 mg pazopanib daily . The study treatment continue subject experience disease progression , unacceptable toxicity , withdrawal consent , death . The primary objective study evaluate safety tolerability pazopanib treatment renal cell carcinoma . The secondary objective study assess response rate ( define complete response partial response ) , progression-free survival , overall survival . Response rate collect per investigator assessment ( central review ) . Subjects CT/MRI scan every 6 week week 24 every 12 week thereafter .</brief_summary>
	<brief_title>Extension Study VEG105192 Assess Pazopanib Patients With Advanced/Metastatic Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Inclusion criterion : Progressed VEG105192 study treatment Patient 's VEG105192 placebo Baseline good organ function Exclusion criterion : No brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>renal cell carcinoma</keyword>
	<keyword>pazopanib</keyword>
	<keyword>anti-angiogenic therapy</keyword>
	<keyword>open label</keyword>
</DOC>